Our data suggest that downregulation of G9a promotes TPCs, leading to disease progression, metastasis, and worse clinical outcome, thus raising caution for the use of G9a inhibitors, particularly for lung cancer treatment. This evidence concerns the gene EHMT2 and lung cancer.